'Something NQR' - the understatement of the year. This management wholly backed a representative should be facing a trial . That says it all about their level of integrity with regards any future plans for the company. What happened with the push into the UK? Seems to me, if they even actually tried, the market is pushing back and refusing to endorse the test. Colostat is dead in the water thanks to them - dead.
RHY Price at posting:
9.5¢ Sentiment: Sell Disclosure: Not Held
